| Dr Paul David Anderson, MD | |
|
169 Ashley Ave, Room 202 Main Hospital Msc333, Charleston, SC 29425-8905 | |
| (843) 876-1344 | |
| Not Available |
| Full Name | Dr Paul David Anderson |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 13 Years |
| Location | 169 Ashley Ave, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366738379 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Anthonys Hospital | Saint petersburg, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greater Florida Anesthesiologists Llc | 3173711017 | 455 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
| Entity Name | Gulf-to-bay Anesthesiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720039746 PECOS PAC ID: 5092628156 Enrollment ID: O20031106000250 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
| Entity Name | Greater Florida Anesthesiologists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528630795 PECOS PAC ID: 3173711017 Enrollment ID: O20101220000829 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
| Entity Name | Root Cause Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962854802 PECOS PAC ID: 6305127408 Enrollment ID: O20170104000653 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
| Entity Name | Luxehealth Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487263166 PECOS PAC ID: 2466865001 Enrollment ID: O20201229000148 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul David Anderson, MD 169 Ashley Ave, Room 202 Main Hospital Msc333, Charleston, SC 29425-8905 Ph: () - | Dr Paul David Anderson, MD 169 Ashley Ave, Room 202 Main Hospital Msc333, Charleston, SC 29425-8905 Ph: (843) 876-1344 |
News Archive
Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.
Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases. The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi's existing sales force.
AARP, the seniors' lobby, has shed as many as 60,000 members in two months over its implicit support for health reform that some members say could lead to Medicare cuts, USA Today reports. The group will launch a campaign next week in hopes of regaining ground with seniors and reestablishing a politically neutral image.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
› Verified 2 days ago
Dr. William Nolan Bagnal, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Main Hospital Msc 333, Charleston, SC 29425 Phone: 843-792-2322 | |
Dr. Bernard Velardo, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Caroline Salvatrice Schlee, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 167 Ashley Avenue, Suite 301 Msc 912, Charleston, SC 29425 Phone: 843-792-2322 | |
Tod A Brown, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2095 Henry Tecklenburg Dr, Charleston, SC 29414 Phone: 843-402-1000 | |
Catherine K Ellyn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 125 Doughty St, Ste 420, Charleston, SC 29403 Phone: 843-723-3441 Fax: 843-805-4040 | |
Dr. Marc Hassid, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Michelle Sher Rovner, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |